Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology • Cholangiocarcinoma • Journal Club ft. NEJM publications
Would you add durvalumab to gem+cis in a patient with recurrent cholangiocarcinoma after liver transplant?
How would you balance the OS benefit from TOPAZ-1 with the risks of immunotherapy in this or other high-risk populations?
Answer from: Medical Oncologist at Community Practice
I would not offer gemcitabine/cisplatin plus durvalumab to a patient with recurrent cholangiocarcinoma after a liver transplant. The added clinical benefit of durvalumab is modest, and the risk of a life threatening liver transplant rejection is high.
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
At this point, I would not without safety data abut losing the transplant data.